• Induced Pluripotent Stem Cell (iPSC) Core
    The Ljubimov Laboratory has an ongoing collaboration with the core on generation and characterization of normal and diabetic iPS cells from cultured ocular surface cells.
  • Nanomedicine Research Center, Department of Neurosurgery
    Our long-term collaboration with the Nanomedicine Research Center concerns design and preclinical testing of various nanobioconjugates of the Polycefin family, used for the MRI-based diagnosis and treatment of cancer and pathological angiogenesis. The polymer bearing various antisense oligos can inhibit growth of human brain, and breast tumors, as well their metastases. The Ljubimov Lab is designing similar nanobiopolymers to treat choroidal neovascularization in a mouse model of macular degeneration. Recently, we started working on a version of this polymer that could be used for diabetic corneal gene therapy.
  • Regenerative Medicine Institute Eye Program
    Dr. Ljubimov is director of the Regenerative Medicine Institute Eye Program that comprises four laboratories studying diabetic eye disease (Alexander Ljubimov, PhD), mechanisms and genetic factors of keratoconus (Yaron Rabinowitz, MD), stem cells as therapies for retinal degenerative diseases (Shaomei Wang, MD, PhD), and the role of microRNA in corneal wound healing and homeostasis (Mehrnoosh Saghizadeh, PhD). Currently, we have five active NIH R01 grants, and a grant from California Institute of Regenerative Medicine (CIRM). Our research is also supported by the Board of Governors Regenerative Medicine Institute grants.
  • Svendsen Laboratory
    Collaboration is ongoing with Svendsen Laboratory on corneal iPS cells, including their generation, characterization, and gene promoter methylation status. This collaboration is supported by two NIH R01 grants.
  • S. Wang Laboratory
    The Ljubimov Laboratory collaborates with the S. Wang Laboratory on preclinical IND-enabling studies of neural progenitor cell transplantation for treatment of retinitis pigmentosa. This collaboration is funded by CIRM.